SEC Form 4 · accession 0001104659-15-016814
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrews R Robbins
Officer — SVP, Commercial Operations
Period of report
Mar 1, 2015
Accepted (ET)
Mar 4, 2015 · 8:16 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 1, 2015 | M | 32,069 | $7.96 | A | 32,069 | D | |
| Common StockF2 | Mar 1, 2015 | F | 10,493 | $7.96 | D | 21,576 | D | |
| Common StockF3 | Mar 2, 2015 | S | 21,576 | $8.25 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4 | — | Mar 1, 2015 | M | 32,069 | D | — | Aug 18, 2018 | Common Stock | 32,069 | 32,069 | D |
Explanation of responses
- F1Shares issued upon settlement of Restricted Stock Units ("RSUs") granted by the Issuer on August 18, 2014 as a result of the vesting of one half of such RSU's.
- F2Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F3The price reflects the weighted average price for the 40,000 shares which were sold in the range of $8.22 - $8.28. Full information about the number of shares sold at each price is available upon request.
- F4RSU's were awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. RSU's representing 32,069 shares of common stock vested on March 1, 2015 and 32,069 shares remain unvested and subject to achievement of a second milestone relating to the return of rights to binimetinib to the issuer on or prior to the fourth anniversary of the grant date, in each case subject to continued service with the Company as of each vesting date.